pharma news today obesity drugs glp-1 health october 2025 Outlook for obesity in 2025: more What is the pipeline for
Description
doi: 10.1053/j.gastro.2015.04.043
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Even modest weight loss dramatically reduces the cytokine output from adipose tissue
Not all researchers were enamored with the data though
By enhancing feelings of fullness, slowing stomach emptying, and supporting healthy insulin response, GLP-1 medications help you eat less and better control your weight and blood sugar
BMJ 339:b2700b2700
